Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry

Mena-Vazquez, N; Fernandez-Nebro, A; Pego-Reigosa, JM; Galindo, M; Melissa-Anzola, A; Uriarte-Isacelay, E; Olive-Marques, A; Aurrecoechea, E; Freire, M; Tomero, E; Garcia-Villanueva, MJ; Stoye, C; Salas-Heredia, E; Bernal-Vidal, JA; Salgado, E; Blanco, R; Novoa, FJ; Ibanez-Barcelo, M; Torrente-Segarra, V; Narvaez, J; Calvet, J; Morales, CM; Vazquez-Rodriguez, TR; de la Pena, PG; Bohorquez, C; Andreu-Sanchez, JL; Cobo-Ibanez, T; Bonilla, G; Lozano-Rivas, N; Montilla, C; Toyos, FJ; De la Fuente, JLM; Exposito, L; Ruiz-Lucea, ME; Vals, E; Manero-Ruiz, J; Rua-Figueroa, I

Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry

Objectives. This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. Methods. RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-s...

Descripción completa

Detalles Bibliográficos
Autores:	Mena-Vazquez, N, Fernandez-Nebro, A, Pego-Reigosa, JM, Galindo, M, Melissa-Anzola, A, Uriarte-Isacelay, E, Olive-Marques, A, Aurrecoechea, E, Freire, M, Tomero, E, Garcia-Villanueva, MJ, Stoye, C, Salas-Heredia, E, Bernal-Vidal, JA, Salgado, E, Blanco, R, Novoa, FJ, Ibanez-Barcelo, M, Torrente-Segarra, V, Narvaez, J, Calvet, J, Morales, CM, Vazquez-Rodriguez, TR, de la Pena, PG, Bohorquez, C, Andreu-Sanchez, JL, Cobo-Ibanez, T, Bonilla, G, Lozano-Rivas, N, Montilla, C, Toyos, FJ, De la Fuente, JLM, Exposito, L, Ruiz-Lucea, ME, Vals, E, Manero-Ruiz, J, Rua-Figueroa, I
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2020
País:	España
Institución:	Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:	r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:	oai:i3pt.fundanetsuite.com:p2824
Acceso en línea:	https://i3pt.portalinvestigacion.com/publicaciones/2824
Access Level:	acceso abierto
Palabra clave:	polyautoimmunity systemic lupus erythematosus multiple autoimmune syndrome

id	ES_28a485ca0085d0ed83082f2c2aa9ca28
oai_identifier_str	oai:i3pt.fundanetsuite.com:p2824
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER RegistryMena-Vazquez, NFernandez-Nebro, APego-Reigosa, JMGalindo, MMelissa-Anzola, AUriarte-Isacelay, EOlive-Marques, AAurrecoechea, EFreire, MTomero, EGarcia-Villanueva, MJStoye, CSalas-Heredia, EBernal-Vidal, JASalgado, EBlanco, RNovoa, FJIbanez-Barcelo, MTorrente-Segarra, VNarvaez, JCalvet, JMorales, CMVazquez-Rodriguez, TRde la Pena, PGBohorquez, CAndreu-Sanchez, JLCobo-Ibanez, TBonilla, GLozano-Rivas, NMontilla, CToyos, FJDe la Fuente, JLMExposito, LRuiz-Lucea, MEVals, EManero-Ruiz, JBernal-Vidal, JARua-Figueroa, Ipolyautoimmunitysystemic lupus erythematosusmultiple autoimmune syndromeObjectives. This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. Methods. RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. Results. Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. Conclusion. Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies.OXFORD UNIV PRESS2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/2824RHEUMATOLOGYISSN: 14620324ISSNe: 14620332reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p28242026-06-21T15:30:37Z
dc.title.none.fl_str_mv	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
title	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
spellingShingle	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry Mena-Vazquez, N polyautoimmunity systemic lupus erythematosus multiple autoimmune syndrome
title_short	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
title_full	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
title_fullStr	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
title_full_unstemmed	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
title_sort	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
dc.creator.none.fl_str_mv	Mena-Vazquez, N Fernandez-Nebro, A Pego-Reigosa, JM Galindo, M Melissa-Anzola, A Uriarte-Isacelay, E Olive-Marques, A Aurrecoechea, E Freire, M Tomero, E Garcia-Villanueva, MJ Stoye, C Salas-Heredia, E Bernal-Vidal, JA Salgado, E Blanco, R Novoa, FJ Ibanez-Barcelo, M Torrente-Segarra, V Narvaez, J Calvet, J Morales, CM Vazquez-Rodriguez, TR de la Pena, PG Bohorquez, C Andreu-Sanchez, JL Cobo-Ibanez, T Bonilla, G Lozano-Rivas, N Montilla, C Toyos, FJ De la Fuente, JLM Exposito, L Ruiz-Lucea, ME Vals, E Manero-Ruiz, J Bernal-Vidal, JA Rua-Figueroa, I
author	Mena-Vazquez, N
author_facet	Mena-Vazquez, N Fernandez-Nebro, A Pego-Reigosa, JM Galindo, M Melissa-Anzola, A Uriarte-Isacelay, E Olive-Marques, A Aurrecoechea, E Freire, M Tomero, E Garcia-Villanueva, MJ Stoye, C Salas-Heredia, E Bernal-Vidal, JA Salgado, E Blanco, R Novoa, FJ Ibanez-Barcelo, M Torrente-Segarra, V Narvaez, J Calvet, J Morales, CM Vazquez-Rodriguez, TR de la Pena, PG Bohorquez, C Andreu-Sanchez, JL Cobo-Ibanez, T Bonilla, G Lozano-Rivas, N Montilla, C Toyos, FJ De la Fuente, JLM Exposito, L Ruiz-Lucea, ME Vals, E Manero-Ruiz, J Rua-Figueroa, I
author_role	author
author2	Fernandez-Nebro, A Pego-Reigosa, JM Galindo, M Melissa-Anzola, A Uriarte-Isacelay, E Olive-Marques, A Aurrecoechea, E Freire, M Tomero, E Garcia-Villanueva, MJ Stoye, C Salas-Heredia, E Bernal-Vidal, JA Salgado, E Blanco, R Novoa, FJ Ibanez-Barcelo, M Torrente-Segarra, V Narvaez, J Calvet, J Morales, CM Vazquez-Rodriguez, TR de la Pena, PG Bohorquez, C Andreu-Sanchez, JL Cobo-Ibanez, T Bonilla, G Lozano-Rivas, N Montilla, C Toyos, FJ De la Fuente, JLM Exposito, L Ruiz-Lucea, ME Vals, E Manero-Ruiz, J Rua-Figueroa, I
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	polyautoimmunity systemic lupus erythematosus multiple autoimmune syndrome
topic	polyautoimmunity systemic lupus erythematosus multiple autoimmune syndrome
description	Objectives. This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. Methods. RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. Results. Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. Conclusion. Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies.
publishDate	2020
dc.date.none.fl_str_mv	2020
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	https://i3pt.portalinvestigacion.com/publicaciones/2824
url	https://i3pt.portalinvestigacion.com/publicaciones/2824
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	OXFORD UNIV PRESS
publisher.none.fl_str_mv	OXFORD UNIV PRESS
dc.source.none.fl_str_mv	RHEUMATOLOGY ISSN: 14620324 ISSNe: 14620332 reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str	Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str	r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection	r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869404957796466688
score	15.811543

Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry

Similares en LA Referencia